Author

Jonathan Bard

CHDI FoundationORCID 0000-0002-5097-1361Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:imaging· 4 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alan MirandaiD· 4 shared Daniele BertoglioiD· 4 shared Longbin LiuiD· 4 shared Steven G. StaelensiD· 4 shared Vinod K. KhetarpaliD· 4 shared Celia DomingueziD· 3 shared Franziska ZajicekiD· 3 shared Jeroen A.J. VerhaegheiD· 3 shared

Activity by Year

2021-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersNeuroscience

Alan MirandaORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

NeuroscienceJournal of Molecular MedicinePeer-reviewedDec 18, 2025

Preclinical evaluation of CHDI-009R for quantification of mutant huntingtin aggregates

Franziska Zajicek, Liesbeth Everix, Annemie Van Eetveldt…·Daniele Bertoglio

This study evaluates [11C]CHDI-009R as a PET radioligand for quantifying mutant huntingtin aggregates in a mouse model of HD, showing high stability, reliability, and genotype differentiation.

2 citations

mouseimaging

𝕏 PostBluesky

NeuroscienceJournal of Cerebral Blood Flow & MetabolismPeer-reviewedDec 4, 2024

Preclinical validation and kinetic modelling of the SV2A PET ligand UCB-J in mice

Liesbeth Everix, Filipe Elvas, Alan Miranda…·Daniele Bertoglio

The paper validates [18F]UCB-J as a selective SV2A PET ligand in mice, showing reliable kinetics and volume of distribution measurements.

3 citations

mouseimaging

𝕏 PostBluesky

NeuroscienceEuropean Journal of Nuclear Medicine and Molecular ImagingPeer-reviewedAug 27, 2024

Preclinical evaluation of the novel CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease

Franziska Zajicek, Jeroen A.J. Verhaeghe, Stef De Lombaerde…·Daniele Bertoglio

This paper evaluates [18F]CHDI-650, a novel PET radiotracer, for imaging mutant huntingtin aggregates in HD mouse models, showing genotype discrimination at 3 and 9 months.

7 citations

mouseimaging

𝕏 PostBluesky

NeurosciencebioRxivPreprintJul 9, 2021

A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington's disease

Daniele Bertoglio, Jonathan Bard, Manuela Heßmann…·Ignacio Muñoz-Sanjuán

This paper develops a PET radioligand to visualize mutant huntingtin levels in the brain and assess therapeutic interventions in Huntington's disease.

2 citations

humanimaging

𝕏 PostBluesky